MAH0 Stock Overview
A biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Mereo BioPharma Group plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.27 |
| 52 Week High | US$4.45 |
| 52 Week Low | US$1.68 |
| Beta | 0.97 |
| 11 Month Change | -21.39% |
| 3 Month Change | -25.00% |
| 1 Year Change | 75.81% |
| 33 Year Change | 81.67% |
| 5 Year Change | 60.29% |
| Change since IPO | -20.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| MAH0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -16.8% | 0.8% | -1.3% |
| 1Y | 75.8% | -17.5% | 7.4% |
Return vs Industry: MAH0 exceeded the German Biotechs industry which returned -16.7% over the past year.
Return vs Market: MAH0 exceeded the German Market which returned 7.1% over the past year.
Price Volatility
| MAH0 volatility | |
|---|---|
| MAH0 Average Weekly Movement | 9.5% |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: MAH0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: MAH0's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 33 | Denise Scots-Knight | www.mereobiopharma.com |
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials.
Mereo BioPharma Group plc Fundamentals Summary
| MAH0 fundamental statistics | |
|---|---|
| Market cap | €529.03m |
| Earnings (TTM) | -€43.23m |
| Revenue (TTM) | €954.00k |
570.0x
P/S Ratio-12.6x
P/E RatioIs MAH0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MAH0 income statement (TTM) | |
|---|---|
| Revenue | US$1.00m |
| Cost of Revenue | -US$273.00k |
| Gross Profit | US$1.27m |
| Other Expenses | US$46.59m |
| Earnings | -US$45.32m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.29 |
| Gross Margin | 127.30% |
| Net Profit Margin | -4,531.60% |
| Debt/Equity Ratio | 7.7% |
How did MAH0 perform over the long term?
See historical performance and comparison